Although stressors appear to motivate marijuana use, and marijuana use, in turn, is believed to induce stress system neuroadaptations, relatively little empirical work has explicitly tested for stress neuroadaptations associated with heavy marijuana use. We examined stressor reactivity to threat of unpredictable electric shock via startle potentiation among heavy marijuana users and a control group that reported minimal history of marijuana use. Heavy marijuana users were randomly assigned to 3 days of marijuana deprivation or no deprivation. This design allowed us to test contrasts for heavy (vs. minimal) use and deprivation (vs. no deprivation) on stressor reactivity. Heavy marijuana users (both deprived and nondeprived) displayed increased startle potentiation during threat of unpredictable electric shock relative to minimal use controls. In contrast, marijuana deprivation had no effect on startle potentiation. Startle potentiation was also increased among users who reported greater stress-coping motives for their marijuana use and users with cannabis use disorder diagnoses. To our knowledge, this is the 1st study to demonstrate increased reactivity to unpredictable stressors among heavy marijuana users. However, comparable increased unpredictable stressor reactivity among patients with alcohol and other substance use disorders has been previously documented. This relationship to heavy marijuana use is consistent with predictions from rodent addiction models regarding stress neuroadaptations following heavy, chronic drug use but could also represent an etiologically relevant premorbid risk characteristic. Finally, the clinical import of unpredictable stressor reactivity is reinforced by its relationships with stress-coping motives and cannabis use disorder status.
between heavy marijuana use and response to stressors, given the key role stressors play in addiction etiology. Although stressors appear to motivate marijuana use (Hyman & Sinha, 2009) , and marijuana use, in turn, is believed to induce stress system neuroadaptations (Fox, Tuit, & Sinha, 2013; Koob & Le Moal, 2008) , relatively little empirical work has explicitly tested for stress neuroadaptations among heavy marijuana users.
Stressors figure prominently in addiction etiology and relapse across drug types (Kaye, Bradford, Magruder, & Curtin, 2017) ; specifically, heavy and/or chronic drug use contributes to heightened behavioral and affective responses to stressors via central nervous system (CNS) mechanisms including corticotrophinreleasing factor (CRF) and norepinephrine (NE) in the central extended amygdala (Koob & Le Moal, 2008) . These stress neuroadaptations in turn result in dysregulated emotional responses to stressors upon cessation of drug use, which provides potent motivation to resume use via craving, increasing relapse risk (Baker, Piper, McCarthy, Majeskie, & Fiore, 2004) across major classes of addictive drugs.
Of particular relevance for marijuana, the endocannabinoid system also regulates CNS response to stressors via modulation of CRF, NE, serotonin, and other stress hormones (Volkow, Hampson, & Baler, 2017) . Additionally, cannabinoid receptor agonists and ⌬ 9 -tetrahydrocannabinol (THC) activate peripheral stress mechanisms via the hypothalamicϪpituitaryϪadrenal axis in humans (D'Souza et al., 2004) and animals (Martín-Calderón et al., 1998) , during both acute administration and withdrawal (Rodrí-guez de Fonseca, Carrera, Navarro, Koob, & Weiss, 1997) . Repeated activation of the endocannabinoid system is thought pivotal to both CNS and peripheral stress system adaptations occurring in heavy marijuana users (Fox et al., 2013; Volkow et al., 2017) , but empirical evidence of stress neuroadaptations in human marijuana users has been lacking. Thus, the first aim of the present study was to test for this predicted increase in stressor reactivity among heavy marijuana users relative to minimal use controls, consistent with this stress neuroadaptation model.
Tonic alterations in mood and/or affective response have been clearly documented during withdrawal from marijuana. The robust marijuana withdrawal syndrome as observed in humans (Budney & Hughes, 2006) and animals (Lichtman & Martin, 2002) involves increased negative affective symptoms (irritability, anger or aggression, nervousness or anxiety; American Psychiatric Association, 2013; Budney & Hughes, 2006; Budney, Hughes, Moore, & Vandrey, 2004; Crippa et al., 2009 ). These negative affective symptoms during withdrawal are reliably reduced or eliminated by the administration of cannabinoid receptor agonist, the main psychoactive component in marijuana. Furthermore, individuals with a marijuana use disorder report this anxiety and negative affect contributes to difficulty abstaining from use and cite relief from withdrawal as a motivation for use (Bonn-Miller & Moos, 2009; Budney & Hughes, 2006; Budney et al., 2004; Coffey et al., 2002; Copersino et al., 2006) . However, it remains unclear whether these affective symptoms result from stress neuroadaptation mechanisms that are enhanced during withdrawal. Therefore, a second aim was to test whether marijuana deprivation increases stressor reactivity among heavy users, consistent with a withdrawal-related impact on stress neuroadaptation mechanisms.
If heavy marijuana use produces stress neuroadaptations that contribute to the etiology and maintenance of cannabis use disorder, individuals who use marijuana to cope with stressors or negative affect may be at heighted risk. Mounting evidence has suggested that stress-coping motives are common among marijuana users (Fox et al., 2013; Green, Kavanagh, & Young, 2003; Hathaway, 2003; Hyman & Sinha, 2009) and are associated with cannabis use disorder, depression, and perceived stress according to the Diagnostic and Statistical Manual of Mental Disorders (5th ed.; DSM-5; American Psychiatric Association, 2013; Moitra, Christopher, Anderson, & Stein, 2015) . More than half of experienced users report blowing off steam, feeling less anxious, and forgetting worries as important reasons for using marijuana (Hathaway, 2003) , whereas nearly three quarters of daily users report using marijuana to relax or relieve tension (Johnston & O'Malley, 1986) . Moreover, heavy marijuana users endorse coping-related motives for their use more than do infrequent users, which may itself result from stress neuroadaptations (Hyman & Sinha, 2009 ). Therefore, a third aim of this study was to conduct exploratory analyses to determine whether marijuana use motives and cannabis use disorder diagnostic status were related to stressor reactivity.
To accomplish these three goals, we quantified stressor reactivity via startle potentiation to unpredictable shock threat, a noninvasive, psychophysiological index of stressor reactivity that is sensitive to putative stress neuroadaptations associated with drug use (Davis, Walker, Miles, & Grillon, 2010; Hogle, Kaye, & Curtin, 2010; Moberg, Bradford, Kaye, & Curtin, 2017) . We chose to use unpredictable shock threat because of translational evidence that implicates CRF and NE mechanisms in the central extended amygdala specifically in response to unpredictable (vs. predictable) threats (Davis et al., 2010; Kaye et al., 2017) . We assessed startle potentiation to these unpredictable threats among deprived (3 days of abstinence from marijuana) and nondeprived heavy marijuana users and a control group on individuals with minimal history of marijuana use. This allowed us to evaluate differences in mean stressor reactivity across heavy marijuana user (deprived and nondeprived heavy users vs. minimal use controls) and deprivation (deprived vs. nondeprived heavy users) contrasts. Furthermore, we assessed individual differences in characteristics regarding marijuana use to evaluate relationships between these individual differences and stressor reactivity.
Method
Study procedures were reviewed and approved by the University of Wisconsin-Madison's Institutional Review Board (protocol: SE-2008 -0164) . We also support emerging open science guidelines (Nosek et al., 2015) providing the data, analysis scripts, questionnaires, and other study materials associated with this report publicly via Open Science Framework (https://osf.io/sgx5c).
Participants
We used flyers and online advertisements to recruit 104 heavy marijuana users (52 female) who reported marijuana use 5 days or more per week, two or more times per day on days when used for 6 months or more (Arnone et al., 2008; Pope & Yurgelun-Todd, 1996) and 52 minimal use controls (26 female) who reported a history of lifetime marijuana use of more than one but less than 50 times and no use in the past month. Participants who reported any recreational drug use (other than alcohol, marijuana, and nicotine) This document is copyrighted by the American Psychological Association or one of its allied publishers.
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resulting in intoxication one or more times per week or with current diagnoses of alcohol or other drug dependence (other than marijuana or nicotine) were excluded from all groups. Participants reporting use of psychotropic medication(s), engagement in psychological treatment (within the last 6 months), or current or past diagnosis of psychotic disorders were also excluded from all groups. A priori power analyses for sample size planning demonstrated that N ϭ 156 provided approximately 86% power to detect a moderate sized between-subjects effect ( p 2 ϭ .06) with an alpha of .05 within the general linear model.
Procedure
Preliminary screening was accomplished when prospective participants called the laboratory to indicate interest in the study. Prospective participants were informed on the phone about the protections of the National Institutes of Health Certificate of Confidentiality associated with this study and provided verbal consent to assess their medical and drug use history. Those meeting preliminary eligibility criteria during the phone contact were scheduled for a subsequent formal screening session in our laboratory. During this screening session, all participants provided informed consent, and a study clinician verified inclusion-exclusion criteria by administering a standardized structured interview to assess their medical history, past and current drug use history (using the alcohol and drug use disorders components of the Mini-International Neuropsychiatric Interview [MINI] adapted to assess past use; Sheehan et al., 1998) , and marijuana use patterns. All participants were asked to provide a urine sample to verify drug use. Minimal use controls were required to test negative on an immediate-result qualitative test of marijuana use using a cutoff score of 50 ng/ml (key operated drug test cup; Drug Test Systems, Dover, NH). Urine samples from heavy users were collected for quantitative comparison analysis.
Deprivation manipulation. Heavy users were randomly assigned to one of two deprivation groups (deprived or nondeprived) in this screening session. Participants assigned to the deprived group were instructed to abstain from any marijuana use (e.g., smoked, ingested) for 3 days prior to their experimental session (described later). Those assigned to the nondeprived group were instructed to maintain their typical frequency and quantity of marijuana use. However, they were instructed to refrain from using marijuana for at least 1 hr before the experimental session to avoid acute intoxication effects in that session. All participants were asked to avoid using alcohol for 24 hr and other recreational drugs (excluding marijuana) for 1 week prior to their experimental session. Those reporting use of nicotine were asked to continue their usual quantity and frequency of use. Minimal use controls were also asked to continue to avoid marijuana use. Participants scheduled their experimental session to occur within 4 -10 days of the screening session.
On arrival for the experimental session, participants reported the dateϪtime of their last marijuana use and any recent (i.e., past 24 hr) alcohol or other (1 week) drug use. Breath alcohol concentration was also assessed. Deprived participants who were noncompliant with abstinence instructions based on urine drug test or their self-report were dismissed and given the opportunity to reschedule once. Any participant indicating noncompliance with the alcohol and/or other drug use requirements was dismissed.
1 Shock threat manipulation. We measured participants' subjective shock tolerance to a series of 200-ms electric shocks of increasing intensity (7 mA maximum) using standard procedures (Curtin, Patrick, Lang, Cacioppo, & Birbaumer, 2001; Hefner & Curtin, 2012; Hefner, Moberg, Hachiya, & Curtin, 2013) . We administered electric shocks using a custom shock stimulator (Bradford, Magruder, Korhumel, & Curtin, 2014) via stainless steel electrodes across the distal phalanges of the index and ring fingers of the left hand. The procedure was discontinued once participants reached the maximum level of shock they could tolerate. We set shock intensity during the main task to each participant's subjective maximum tolerance threshold to minimize individual differences in shock tolerance.
Participants were administered unpredictable shocks in the context of a reward decision-making task 2 in which they pressed buttons to indicate preferred rewards. This task was designed to address other questions that are not a focus of the present investigation (Hefner, Starr, & Curtin, 2016) . Participants completed the task in unpredictable alternating blocks of "unpredictable shock threat" or "no shock." In unpredictable-shock-threat blocks, participants were instructed that electric shocks were unpredictable and could occur at any point during the block, whereas in no-shock blocks, shocks would never be administered. To increase manipulation salience, the experimenter verbally identified block type and reiterated shock contingencies at the beginning of each block. Finally, a block label (e.g., NO SHOCKS) remained on the screen in the top left corner throughout the block. Participants completed four total blocks of trials (two each) in one of four between-subjects counterbalanced orders. A total of five shocks were administered throughout the main session, three in the first unpredictable-shockthreat block and two in the second. Similar procedures have been used successfully and reliably produce robust startle potentiation during unpredictable-shock-threat blocks relative to no-shock blocks (Hefner & Curtin, 2012; Hefner et al., 2013; Hogle et al., 2010; McCarthy, Gloria, & Curtin, 2009). 1 No participants in either group were disqualified for a positive breath alcohol concentration at the experimental session. Similarly, no participants in the deprived group were disqualified because of a positive urine drug test indicating recent marijuana use prior to the experimental session. One participant was disqualified from the deprived group due to abstaining for 7 days. Two participants in the nondeprived group were disqualified for self-reported use of drugs (other than marijuana) within 1 week of the experimental session. Finally, four participants in the deprived group and seven participants in the nondeprived group were lost to attrition between the screening and experimental session.
2 The task included 144 trials where participants were presented with a choice between a "certain" and "uncertain" monetary reward. Each certain reward was associated with a clear, single monetary value. Uncertain rewards involved the equiprobable receipt of one of two different monetary values. Each trial included a choice between one certain versus one uncertain (two possible values) reward. The values of the certain reward and the mean value and range of the two uncertain reward options were varied parametrically across trials. Participants pressed a button to indicate which of these two rewards they would prefer to receive at the end of the experiment. Participants did not receive any feedback trial-by-trial and were paid a bonus at the end of the experiment based on their preferred reward on one randomly selected trial. This document is copyrighted by the American Psychological Association or one of its allied publishers.
Measures
Stable individual difference measures. The MINI (Sheehan et al., 1998 ) was used to diagnose marijuana or other drug abuse and dependence and was adapted to assess past abuse and dependence in all participants. Participants also self-reported any history of (a) anxiety, (b) depression, or (c) other psychiatric diagnoses or treatment. All participants completed the Depression Anxiety and Stress Scales-21 (DASS-21; Lovibond & Lovibond, 1995) , adapted to assess symptoms over the past 30 days rather than past week. Cronbach's alphas were .65, .82, and .80 for Anxiety, Depression, and Stress subscales, respectively, in this sample. All participants completed the Marijuana Motives Measure (MMM; Simons, Correia, Carey, & Borsari, 1998) to assess motivations for using marijuana. Cronbach's alphas were . 80, .92, .86, .93, and .83 for the Conformity, Stress Coping, Enhancement, Expansion, and Social subscales, respectively, in this sample. Heavy marijuana users reported their approximate quantity of weekly use.
Deprivation-related manipulation checks. All participants completed the Marijuana Withdrawal Checklist (MWC; Budney, Novy, & Hughes, 1999; Vandrey, Budney, Moore, & Hughes, 2005) and Marijuana Craving Questionnaire (MCQ; Heishman, Singleton, & Liguori, 2001 ) at both screening and experimental sessions to assess changes in withdrawal symptoms and craving. Cronbach's alphas were .52 and .86 for the MWC and .88 and .89 for the MCQ at screening and experimental sessions, respectively. Heavy marijuana users also reported the time of their last marijuana use.
Startle response. Electromyographic activity in the orbicularis oculi muscle was sampled at 2000 Hz with a bandpass filter (.05-500 Hz) from electrodes placed under the right eye according to published guidelines (Blumenthal et al., 2005; Van Boxtel, 1998) . Eyeblink startle response was measured in response to startle-eliciting noise probes (50 ms of 102-dB white noise with near instantaneous rise time). Twenty-four noise probes were presented during a subset of trials during unpredictable-and noshock blocks). Data reduction and processing followed published guidelines (Blumenthal et al., 2005) . We performed offline processing in Matlab using EEGLab (Delorme & Makeig, 2004) and PhysBox (Curtin, 2011) plugins. This processing included high pass filtering (28 Hz, 4th-order Butterworth, zero phase shift), rectification, smoothing (30 Hz, 2nd-order Butterworth low-pass filter, zero phase shift), epoching (Ϫ50 to 250 ms surrounding probe), and baseline correction. Startle magnitude was scored as the peak response between 20-and 100-ms post probe onset. We rejected trials containing an artifact, consistent with standard practices from our laboratory (Kaye, Bradford, & Curtin, 2016) . This included trials with deflections greater than Ϯ20 V in the 50-ms preprobe baseline (i.e., unstable baseline) and trials with mean activity ՅϪ10 V between 150 and 250 ms post probe onset (i.e., baseline overcorrection due to preepoch artifact). Startle potentiation was calculated as the increase in startle magnitude during unpredictable-shock relative to no-shock blocks. We also calculated general startle reactivity as mean startle magnitude to six noise probes presented prior to the start of the task. Following previous recommendations (Bradford, Kaye, & Curtin, 2014) , we used general startle reactivity as a covariate in all analyses of startle potentiation to increase power to detect focal effects.
Urinalysis of marijuana use. Urine samples from heavy users were obtained at both screening and experimental sessions for quantitative analysis to verify compliance with the abstinence instructions for the deprived users. A specimen ratio of creatinine-normalized samples at two different time points (Creatinine-Normalized Specimen 2/Creatinine-Normalized Specimen 1) was used to detect recent use among marijuana users assigned to abstain from marijuana (Huestis & Cone, 1998) . Following previously established procedures and cutoff scores to detect recent drug use among abstaining individuals, we considered deprived users with specimen ratios exceeding 1.5 noncompliant with the abstinence requirement. (Huestis & Cone, 1998; Manno, Ferslew, & Manno, 1984) . This specimen ratio has not been used previously to confirm continued use among regular (nonabstinent) marijuana users, and no information about its sensitivity or specificity for that purpose exists to our knowledge. Therefore, we limited its use to confirming no recent use among deprived heavy users; however, we collected and calculated specimen ratios in all heavy users to allow for quantitative comparisons across groups as a manipulation check.
Results
Data analysis and figure preparation were accomplished with R (R Core Team, 2015) within RStudio using the lmSupport (Curtin, 2015) package. We use general linear models (GLMs) for all analyses unless otherwise noted. Marijuana group effects were analyzed with two planned orthogonal contrasts: the heavy marijuana user contrast (deprived and nondeprived heavy users vs. minimal use controls) and the deprivation contrast (deprived vs. nondeprived heavy marijuana users). We report 95% confidence intervals (CIs) for raw parameter estimates (b) and also p 2 from the GLMs to document effect sizes.
Group Comparisons on Affect and MarijuanaRelevant Individual Differences
Means, standard deviations, and p values for the two marijuana group contrasts for the affect and marijuana-relevant individual difference measures are reported in Table 1 . None of the deprivation contrasts were significant for any of the individual difference measures, as expected given that heavy users were randomly assigned to the deprived and nondeprived groups. Significant heavy marijuana user contrasts were observed for all individual difference measures. 
Marijuana Deprivation Manipulation Checks
Means, standard deviations, and p values for the deprivation contrast on self-report and biological confirmation of marijuana This document is copyrighted by the American Psychological Association or one of its allied publishers.
use, marijuana withdrawal, and marijuana craving are reported in 
Marijuana Group Effects on Startle Potentiation
Startle potentiation 3 was analyzed in a GLM with betweensubjects regressors for the heavy marijuana user and deprivation planned orthogonal contrasts. General startle reactivity (meancentered) and order (Order 1 vs. Order 2) were included as interactive covariates. As expected, significant nonzero startle potentiation was observed ( p 2 ϭ .49, b ϭ 37.8, 95% CI [31.4, 44.2]), t(141) ϭ 11.69, p Ͻ .001, such that startle response was significantly potentiated during unpredictable-shock-threat compared to no-shock blocks. The heavy marijuana user contrast was significant ( p 2 ϭ .03, b ϭ 15.0, 95% CI [1.5, 28.5]), t(141) ϭ 2.20, p ϭ .029, indicating that heavy marijuana users displayed approximately 15 V greater startle potentiation to threat of unpredictable shock compared to controls (see Figure 1) . The deprivation contrast was not significant ( p 2 Ͻ .01, b ϭ Ϫ1.4, 95% CI [Ϫ17.2, 14.4]), t(141) ϭ .18, p ϭ .861, indicating comparable startle potentiation across deprived and nondeprived heavy users.
Supplemental robustness analyses evaluated the just-reported significant heavy marijuana user contrast while controlling for all non-marijuana-use-relevant individual differences listed in Table 1 (i.e., age; sex; race; Hispanic ethnicity; DASS scales; and selfreport of anxiety, depression, or any psychiatric diagnosis or treatment, drinks per week, cigarettes per week, or smoker status) by including each of these individual differences as a covariate in separate analyses. Cannabis use disorder diagnoses and marijuana use motives were not considered as covariates in these analyses because variance on these measures is inherent to group membership in the heavy user groups (Miller & Chapman, 2001 ). The heavy marijuana user contrast remained significant across all models controlling for these covariates (individual p values for this contrast ranged from .022 to .047).
Marijuana-Relevant Individual Differences and Startle Potentiation
To clarify the observed significant heavy marijuana user contrast, we conducted follow-up analyses of marijuana-relevant individual differences measures (i.e., marijuana use motives, diagnostic status). Each of these individual difference variables was examined in separate GLMs that included general startle reactivity and order as interactive covariates per the primary analysis of marijuana group reported earlier. Given the exploratory nature of these follow-up analyses, we report both raw and false discovery rate (FDR) corrected p values (Benjamini & Hochberg, 1995) for these statistical tests.
Participants who reported greater stress-coping motives for their marijuana use displayed significantly increased startle potentiation ( p 2 ϭ .05, b ϭ 2.4, 95% CI [.7, 4 .1]), t(145) ϭ 2.81, p ϭ .006, FDR-corrected p ϭ .031 (see Figure 2A) . 4 Figure 2B ).
3 Three participants were identified as Bonferroni-corrected outliers (p Յ .05) in these analyses and were therefore removed from all analyses of startle potentiation. However, the focal heavy marijuana user contrast remains significant if these participants are retained. 4 This effect for stress-coping motives remained significant in a supplemental model that examined its unique effect controlling for all other coping motives and participants' extent of marijuana use (i.e., grams of use/week; p 2 ϭ .03, b ϭ 2.7, 95% confidence interval [.2, 5 .1]), t(140) ϭ 2.17, p ϭ .032. Also consistent with the other analyses, none of the other motives scales had significant unique effects in this model. This article is intended solely for the personal use of the individual user and is not to be disseminated broadly.
Discussion

Stress Neuroadaptation in Heavy Marijuana Use
We investigated stressor reactivity among deprived and nondeprived heavy marijuana users and minimal use controls to test for predicted stress neuroadaptations that may result from heavy marijuana use. We observed that heavy marijuana users (both deprived and nondeprived) displayed increased startle potentiation during threat of unpredictable electric shock relative to minimal use controls. To our knowledge, this is the first study to demonstrate increased reactivity to unpredictable stressors among heavy marijuana users in a manner comparable to exaggerated stressor reactivity among users of other drugs. Specifically, Moberg and colleagues (2017) reported that alcohol-dependent participants in early abstinence (Ͻ8 weeks) displayed increased startle potentiation to unpredictable (vs. predictable) shock threat relative to healthy controls. Similarly, Gorka, Nelson, and Shankman (2013) demonstrated increased startle potentiation during unpredictable shock threat in participants with comorbid alcohol dependence and panic disorder relative to both participants with only panic disorder and healthy controls. Furthermore, Grillon, Avenevoli, Daurignac, and Merikangas (2007) confirmed increased startle potentiation during blocks of unpredictable but not predictable air blast cues in overnight-deprived smokers relative to nonsmokers.
Synthesis of these studies provides emerging support that is consistent with the stress neuroadaptation model in the etiology of alcohol and other drug (AOD) addiction . Rodent addiction models posit that repeated homeostatic adjustments in brain stress systems to acute periods of AOD intoxication eventually lead to long-lasting, compensatory allostatic changes in CNS structures and circuits involved in behavioral and emotional response to stressors (i.e., stress neuroadaptations; Koob & Le Moal, 2008) . Substantial evidence has suggested that specific adaptations in CRF-and NE-sensitive pathways in the central extended amygdala contribute importantly to increased stressor reactivity in rodents, including stress-induced reinstatement of drug use (for reviews see Mantsch, Baker, Funk, Lê, & Shaham, 2016; Silberman & Winder, 2013; Smith & Aston-Jones, 2008) . It is important to note that basic affective science research with both humans and rodents have validated startle potentiation selectively to unpredictable stressors as a sensitive index of these stress mechanisms. Thus, increased startle potentiation to unpredictable threat among heavy users of marijuana, alcohol, and/or tobacco in humans is consistent with both increased stressor reactivity and the neural mechanisms proposed by the rodent stress neuroadaptation model. Future research in humans can strengthen evidence for neural mechanisms by direct pharmacologic manipulation of these neurotransmitter systems while measuring unpredictable stressor startle potentiation in AOD dependent users (e.g., National Institute on Alcohol Abuse and Alcoholism [NIAAA] R01-AA024388). Moreover, future research should explore other marijuana use characteristics (e.g., chronicity, patterns of episodic use such as bingeϪwithdrawal) that may contribute to neuroadaptations in stressor reactivity.
Although results from recent studies have been consistent with the stress neuroadaptation model, the exclusive use of cross-sectional designs with preexisting groups across these studies does not provide definitive evidence of drug-related changes, and this allows for other plausible interpretations. In particular, increased startle potentiation to unpredictable stressors may represent a premorbid risk factor for AOD use disorders rather than merely a consequence of chronic AOD use (Gorka, Lieberman, Phan, & Shankman, 2016; Rasmussen & Kincaid, 2015) . Moreover, these factors may work in tandem, such that premorbid risk involving heightened startle potentiation contrib- This article is intended solely for the personal use of the individual user and is not to be disseminated broadly.
utes to AOD use, which subsequently exacerbates stressor reactivity over time. Additional research including longitudinal designs to document within-subject change in stressor reactivity following heavy and/or chronic use is necessary to adjudicate between alternative but mutually tenable interpretations. Such research would also address ambiguity regarding other possible confounding variables that may differ when comparing the heavy and minimal use groups, variables that might explain differences in stressor reactivity between the two groups. Our use of covariates to control for some key individual differences reduces but cannot eliminate concern about such confounds.
Stressor Reactivity During Marijuana Deprivation
With respect to our second aim, we did not observe any impact of marijuana deprivation on startle potentiation to unpredictable shock threat among heavy users. This null result was observed despite clear evidence of a successful deprivation manipulation, wherein compliance was verified by both self-report and urinalysis. Furthermore, deprived heavy users reported significantly more intense withdrawal symptoms and negative affect symptoms, as well as greater craving, than did nondeprived heavy users. These results support that our deprived heavy users experienced a robust withdrawal syndrome including expected increases in negative affect. Nonetheless, marijuana withdrawal did not appear to influence their stressor reactivity.
The null effect of marijuana deprivation on unpredictable startle potentiation suggests potentially distinct mechanisms may be responsible for (a) the increased stressor reactivity observed among all heavy marijuana users and (b) the increased subjective negative affect displayed by deprived heavy users only, respectively. This distinction has support from rodent models; specifically, NE and CRF mechanisms proposed to experience neuroadaptations following chronic drug use support "dynamic, active response to an acute stressor" rather than tonic, persistent negative mood states (Koob & Zorrilla, 2012, p. 309 ; also see Heilig, Goldman, Berrettini, & O'Brien, 2011 ).
Thus, it appears possible that heavy marijuana users may experience two forms of affective disruption that could motivate further use or prompt relapse after cessation of use. Unpredictable stressors may elicit punctate, exaggerated reactivity that increases the reward value of further marijuana use during stressful periods. These phasic increases in drug use motivation may further be layered on top of tonically increased negative affect resulting from deprivation and also provide strong motivation for further use and/or relapse (Baker et al., 2004; Curtin, McCarthy, Piper, & Baker, 2006) .
Of course, increased confidence in this dual mechanism thesis for marijuana and other drugs requires additional investigation. For example, it is possible that we did not observe a deprivation effect because reactivity to unpredictable threat may represent a stable risk marker that does not vary across periods of marijuana use and abstinence. Alternatively, this null effect for changes in stressor reactivity during marijuana deprivation could be a Type II error, though it should be acknowledged that we had adequate power to detect such an effect (86% power to detect a moderate-sized between-subjects effect). Nonetheless, confidence in this null effect would be increased with replication that used potentially more powerful within-subject manipulations of deprivation. This effect must also be scrutinized for other commonly used illicit drugs. For example, to our knowledge, short-term drug deprivation effects on unpredictable stressor reactivity have not been examined for alcohol or opiates, two drugs that produce potent withdrawal syndromes. Two studies have examined the effects of tobacco deprivation on unpredictable stressor reactivity using startle potentiation, but the results were inconsistent. Hogle and colleagues (2010) observed increased startle response to unpredictable shock threat among deprived relative to nondeprived smokers, but they did not include nonsmokers. In contrast, Grillon and colleagues (2007) reported increased startle potentiation to unpredictable air blasts among deprived smokers versus nonsmokers but no differences between deprived and nondeprived smokers. Given the paucity of evidence, we consider it premature to draw definitive conclusions about the impact of drug deprivation across drug classes on stressor reactivity (see Kaye et al., 2017 , for further discussion of possible deprivation-withdrawal mechanisms).
Individual Differences in Stressor Reactivity
Our third aim was to examine relationships between individual differences in stressor reactivity and measures of marijuana use motives and marijuana use diagnostic status. As expected, heavy marijuana users reported stronger motives for marijuana use than did minimal use controls across all motives (i.e., enhancement, expansion, social, and stress coping) other than conformity. However, stresscoping motives was unique in its relationship with startle potentiation to unpredictable shock threat. Participants reporting greater stresscoping motives for marijuana use displayed increased startle potentiation during unpredictable stressor exposure. This relationship could emerge through varied etiologic pathways. If heavy marijuana use had increased stressor reactivity per the stress neuroadaptation model, users who may have experienced this neuroadaptation would be expected to use marijuana to dampen or otherwise cope with increased reactivity as it emerged over time. Support for this hypothesis would be strengthened by evidence that acute marijuana use dampened unpredictable threat startle potentiation, as has been demonstrated for other anxiolytic drugs (Baas et al., 2002; Bradford, Motschman, Starr, & Curtin, 2017; Bradford, Shapiro, & Curtin, 2013; Grillon et al., 2006; Hefner et al., 2013) . Alternatively, if increased stressor reactivity were a premorbid risk factor for heavy marijuana use, use of marijuana to cope may represent an initial motive that itself leads to heavy use. This notwithstanding, the likely clinical importance of unpredictable threat startle potentiation is made salient by its unique relationship with stress coping motives. Startle potentiation to unpredictable threat also varied systematically by diagnostic status, with higher means observed for participants with marijuana dependencies versus marijuana abuse versus no diagnosis, further underscoring its clinical import.
Limitations and Future Directions
Synthesis of our results indicates that increased startle potentiation (a) was observed among heavy users versus minimal use controls, (b) was associated with increasing stress-coping motives, and (c) was associated with increased diagnostic severity for marijuana use disorder. Similar increased startle potentiation to unpredictable threat has been confirmed among individuals with AOD use disorders. This highlights heightened phasic stressor reactivity as a potential etiologically relevant mechanism across addictive drugs as proposed by the stress neuroadaptation model. Furthermore, it makes salient a potentially important negative consequence that may result from heavy use of any addictive drug, This document is copyrighted by the American Psychological Association or one of its allied publishers.
including marijuana. However, cross-sectional designs like that of the present study are not sufficient to establish stress neuroadaptation and do not exclude the possibility that the observed effects resulted from premorbid risk-related individual differences. As noted earlier, increased confidence in these claims will require longitudinal designs to clearly document within-subject change following heavy, chronic drug use. Nonetheless, we believe that confirmation of these group differences in stressor reactivity as predicted by the stress neuroadaption model in a cross-sectional design was a necessary prerequisite to justify subsequent costlier longitudinal designs to definitively test for within-subject change.
Research with other drugs has also specifically implicated reactivity to unpredictable (vs. predictable) stressors. Unfortunately, the current study did not include a predictable stressor condition. Future research should also use methods (e.g., pharmacological challenge with neurotransmitter agonists and antagonists) and measures (e.g., functional magnetic resonance imaging, positron emission tomography) that enable more precise specification of the neural mechanisms accounting for increased stressor reactivity. For now, inference about neural mechanism rests primarily on the tight translation of both measure (startle potentiation) and methods (unpredictable shock threat) from preclinical research with rodents (Davis et al., 2010) . Furthermore, it should be acknowledged that stressor reactivity was assessed in this study in the context of a reward decision-making task. Reward-related processes should not have confounded heavy user or deprivation contrasts, because all groups completed this decision-making task. However, this leaves open questions about whether these stressor reactivity effects generalize to situations without concurrent focus on rewards.
More broadly, the National Institute of Mental Health has begun to advocate for an experimental therapeutics approach in clinical research that simultaneously evaluates intervention efficacy and mechanism in clinical trials research (Insel, 2015; Insel & Gogtay, 2014) . This approach requires that clinical trials explicitly measure pertinent mechanism(s) of either the disease process or the action of the intervention. In particular, the use of "surrogate endpoints"-early markers of disease process mechanisms with high predictive validity for later clinical outcomes-offer high promise to increase the pace of clinical trials research to develop and refine medications and other interventions for psychopathology broadly, including substance use disorders (Insel, 2012; Lerman et al., 2007; Litten, Falk, Ryan, & Fertig, 2016; McKee, 2009) . We believe that data from this and other recent studies support the use of startle potentiation to unpredictable threat as a surrogate end point to study stress mechanisms in addiction using an experimental therapeutics approach (for review, see .
Finally, the focus on an etiological pathway involving increased stressor reactivity, either premorbidly or as a consequence of heavy use, highlights an important target for treatment. Clinical trials are under way to examine the use of NE alpha1 antagonist medications (e.g., prazosin, doxazosin; NIAAA R01-AA024388) to target stress-induced relapse in substance use disorders, consistent with mechanisms we propose here (for review, see Mantsch et al., 2016 ). More precise targeting of sources and coping strategies for unpredictable stressors may increase the efficacy of psychological interventions for addiction. Relapse prevention programs can help patients to better identify risks by explicit, personalized assessment of stressors in their lives that are both potent and characterized by a high degree of uncertainty. These programs can also help patients develop tools to reshape their environments and social interactions to reduce unpredictability (e.g., problemsolving to address uncertain financial, housing, or interpersonal stresses; practicing direct communication with others to clarify stressful but ambiguous interpersonal exchanges). This focus on reactivity to unpredictable stressors also reinforces the potential benefits offered by existing but often unavailable or underfunded harm reduction approaches that robustly reduce uncertainty for drug-dependent users regarding some of the more potent and unpredictable stressors involving housing, health, and other basic needs (Newman & Goldman, 2008) . We believe that such multifaceted approaches involving medications, psychosocial interventions, and public health initiatives offer the most promise to address the high costs of AOD use disorders generally, including any increase in rates of marijuana use disorder that may result from changing perceptions and regulations of this drug.
